These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10340602)

  • 1. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.
    Ohkubo M; Kojiri K; Kondo H; Tanaka S; Kawamoto H; Nishimura T; Nishimura I; Yoshinari T; Arakawa H; Suda H; Morishima H; Nishimura S
    Bioorg Med Chem Lett; 1999 May; 9(9):1219-24. PubMed ID: 10340602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
    Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
    Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy- 13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole- 5,7(6H)-dione (NB-506): its potent antitumor activities in mice.
    Arakawa H; Iguchi T; Morita M; Yoshinari T; Kojiri K; Suda H; Okura A; Nishimura S
    Cancer Res; 1995 Mar; 55(6):1316-20. PubMed ID: 7882329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
    J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.
    Takenaga N; Ishii M; Nakajima S; Hasegawa T; Iwasa R; Ishizaki H; Kamei T
    Drug Metab Dispos; 1999 Feb; 27(2):205-12. PubMed ID: 9929504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
    Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
    Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I.
    Yoshinari T; Ohkubo M; Fukasawa K; Egashira S; Hara Y; Matsumoto M; Nakai K; Arakawa H; Morishima H; Nishimura S
    Cancer Res; 1999 Sep; 59(17):4271-5. PubMed ID: 10485471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
    Facompre M; Carrasco C; Colson P; Houssier C; Chisholm JD; Van Vranken DL; Bailly C
    Mol Pharmacol; 2002 Nov; 62(5):1215-27. PubMed ID: 12391286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.
    Takenaga N; Hasegawa T; Ishii M; Ishizaki H; Hata S; Kamei T
    Drug Metab Dispos; 1999 Feb; 27(2):213-20. PubMed ID: 9929505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indolocarbazole glycosides in inactive conformations.
    Facompré M; Carrasco C; Vezin H; Chisholm JD; Yoburn JC; Van Vranken DL; Bailly C
    Chembiochem; 2003 May; 4(5):386-95. PubMed ID: 12740810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.
    Cavazos CM; Keir ST; Yoshinari T; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):250-4. PubMed ID: 11592348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings.
    Ohkubo M; Nishimura T; Honma T; Nishimura I; Ito S; Yoshinari T; Suda HA; Morishima H; Nishimura S
    Bioorg Med Chem Lett; 1999 Dec; 9(23):3307-12. PubMed ID: 10612590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and anticancer activity of new pyrrolocarbazoles and pyrrolo-beta-carbolines.
    Laronze M; Boisbrun M; Léonce S; Pfeiffer B; Renard P; Lozach O; Meijer L; Lansiaux A; Bailly C; Sapi J; Laronze JY
    Bioorg Med Chem; 2005 Mar; 13(6):2263-83. PubMed ID: 15830466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activities of NB-506 analogues modified at the glucose group.
    Ohkubo M; Nishimura T; Kawamoto H; Nakano M; Honma T; Yoshinari T; Arakawa H; Suda H; Morishima H; Nishimura S
    Bioorg Med Chem Lett; 2000 Mar; 10(5):419-22. PubMed ID: 10743939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rebeccamycin analogues from indolo[2,3-c]carbazole.
    Voldoire A; Sancelme M; Prudhomme M; Colson P; Houssier C; Bailly C; Léonce S; Lambel S
    Bioorg Med Chem; 2001 Feb; 9(2):357-65. PubMed ID: 11249128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
    Balasubramanian BN; St Laurent DR; Saulnier MG; Long BH; Bachand C; Beaulieu F; Clarke W; Deshpande M; Eummer J; Fairchild CR; Frennesson DB; Kramer R; Lee FY; Mahler M; Martel A; Naidu BN; Rose WC; Russell J; Ruediger E; Solomon C; Stoffan KM; Wong H; Wright JJ; Zimmermann K; Vyas DM
    J Med Chem; 2004 Mar; 47(7):1609-12. PubMed ID: 15027851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents.
    Bailly C; Dassonneville L; Colson P; Houssier C; Fukasawa K; Nishimura S; Yoshinari T
    Cancer Res; 1999 Jun; 59(12):2853-60. PubMed ID: 10383146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agents.
    Zembower DE; Xie Y; Koohang A; Kuffel MJ; Ames MM; Zhou Y; Mishra R; Mar AA; Flavin MT; Xu ZQ
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1117-31. PubMed ID: 22339065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.